Anti-SARS-CoV-1, Spike (Clone COV1-57)-Purified No Carrier Protein, Clone: [COV1-57], Monoclonal
Artikelnummer:
ABI-12-8258-250
Hersteller Artikelnummer:
12-8258-250
Alternativnummer:
ABI-12-8258-250-250UG
Hersteller:
Abeomics
Kategorie:
Antikörper
Specificity: COV1-57 is highly specific for the SARS-CoV-1 and SARS-CoV-2 prefusion spike protein (S2) distributed on the viral surface. Antigen Distribution: Anti-SARS-CoV-1 recognizes antigens on infected cells, including respiratory epithelial cells. Background: SARS-CoV-1, also known as the Severe Acute Respiratory Syndrome coronavirus, is a zoonotic virus that is believed to have originated from an animal reservoir, possibly horseshoe bats, and transmitted to humans1. This virus primarily affects the respiratory system and can cause symptoms such as muscle pain, headache, fever, cough, dyspnea, and pneumonia1,2. It was the first severe and readily transmissible new disease to emerge in the 21st century, with the capacity to spread globally via international air travel. The COV1-57 monoclonal antibody targets the prefusion spike protein of both SARS-CoV-1 and SARS-CoV-2, making it a cross-reactive antibody. Although it does not block the ACE2 receptor, COV1-57 functions as a neutralizing antibody, which means it can inhibit the viruss ability to infect host cells. The neutralizing activity of COV1-57 suggests that it can prevent the spike protein from undergoing the necessary conformational changes required for membrane fusion. The specific epitope targeted by COV1-57 remains unknown, which warrants further research to determine the precise binding site and mechanism of neutralization. This antibody could be valuable in therapeutic applications, especially in combination with other antibodies that target different epitopes.
Klonalität:
Monoclonal
Klon-Bezeichnung:
[COV1-57]
Reinheit:
Purity: >=90% monomer by analytical SEC and SDS-Page Preparation: Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Target-Kategorie:
SARS-CoV-1
Application Verdünnung:
N
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
